Oxycodone Patent Expiration
Oxycodone is Used for managing severe, chronic pain when other treatment options are insufficient. It was first introduced by Collegium Pharmaceutical Inc
Oxycodone Patents
Given below is the list of patents protecting Oxycodone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xtampza Er | US10188644 | Process of making stable abuse-deterrent oral formulations | Sep 02, 2036 | Collegium Pharm Inc |
| Xtampza Er | US10646485 | Process of making stable abuse-deterrent oral formulations | Sep 02, 2036 | Collegium Pharm Inc |
| Xtampza Er | US9737530 | Process of making stable abuse-deterrent oral formulations | Sep 02, 2036 | Collegium Pharm Inc |
| Xtampza Er | US9968598 | Process of making stable abuse-deterrent oral formulations | Sep 02, 2036 | Collegium Pharm Inc |
| Xtampza Er | US10004729 | Tamper-resistant pharmaceutical compositions of opioids and other drugs | Dec 10, 2030 | Collegium Pharm Inc |
| Xtampza Er | US10668060 | Tamper-resistant pharmaceutical compositions of opioids and other drugs | Dec 10, 2030 | Collegium Pharm Inc |
| Xtampza Er | US9682075 | Tamper-resistant pharmaceutical compositions of opioids and other drugs | Dec 10, 2030 | Collegium Pharm Inc |
| Xtampza Er | US8758813 | Abuse-deterrent drug formulations | Jun 10, 2025 | Collegium Pharm Inc |
| Xtampza Er | US7399488 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
Mar 24, 2025
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US7771707 | Abuse-deterrent drug formulations |
Mar 24, 2025
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US8449909 | Abuse-deterrent drug formulations |
Mar 24, 2025
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US8557291 | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Mar 21, 2025
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US10525052 | Abuse-deterrent drug formulations |
Jul 07, 2023
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US10525053 | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul 07, 2023
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US8840928 | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Jul 07, 2023
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US9044398 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
Jul 07, 2023
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US9248195 | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul 07, 2023
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US9592200 | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul 07, 2023
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US9763883 | Abuse-deterrent drug formulations |
Jul 07, 2023
(Expired) | Collegium Pharm Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Oxycodone's patents.
Latest Legal Activities on Oxycodone's Patents
Given below is the list recent legal activities going on the following patents of Oxycodone.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Second letter to regulating agency to determine regulatory review period | 20 Mar, 2024 | US7771707 |
| Second letter to regulating agency to determine regulatory review period | 20 Mar, 2024 | US7399488 |
| Requirement for information sent under 37 CFR 1.750 | 20 Mar, 2024 | US7771707 |
| Second letter to regulating agency to determine regulatory review period | 20 Mar, 2024 | US8449909 |
| Expire Patent Critical | 12 Feb, 2024 | US10525053 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Nov, 2023 | US10668060 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 25 Oct, 2023 | US10646485 |
| Letter from FDA or Dept of Agriculture re PTE application | 19 Oct, 2023 | US7399488 |
| Letter from FDA or Dept of Agriculture re PTE application | 19 Oct, 2023 | US7771707 |
| Maintenance Fee Reminder Mailed Critical | 28 Aug, 2023 | US10525053 |
Oxycodone's Family Patents
